NEUCA S.A.

Warsaw Stock Exchange NEU.WA

NEUCA S.A. EBITDA for the year ending December 31, 2023: USD 101.90 M

NEUCA S.A. EBITDA is USD 101.90 M for the year ending December 31, 2023, a 26.68% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

NEUCA S.A. EBITDA for the year ending December 31, 2022 was USD 80.43 M, a 10.81% change year over year.
NEUCA S.A. EBITDA for the year ending December 31, 2021 was USD 72.59 M, a -0.98% change year over year.
NEUCA S.A. EBITDA for the year ending December 31, 2020 was USD 73.30 M, a 24.58% change year over year.
NEUCA S.A. EBITDA for the year ending December 31, 2019 was USD 58.84 M, a 15.82% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Warsaw Stock Exchange: NEU.WA

NEUCA S.A.

CEO	Mr. Piotr Sucharski
IPO Date	Nov. 22, 2004
Location	Poland
Headquarters	ul. Forteczna 35-37
Employees	4,633
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments. The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, telemedicine, agency, financial, road cargo transport, accounting and bookkeeping, software, hospital, and information technology and computer related services; and health, property, and other personal insurance products. In addition, it operates outpatient care clinics and medical stores. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.

Key trends

Past 5 years